StreetAlpha.app
Home › Stocks › DARE

Dare Bioscience, Inc. (DARE)

$0.43
▼ −26.57%
LAST CLOSE · NOV 17

Dare Bioscience develops women's health drugs and consumer products for areas such as contraception, menopause, and sexual health. It last closed at $0.43 on Nov 17, down 26.57% on the day.

AI Auto Pilots
Is DARE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.4M
Net income
−$10.6M
−749.8% margin
EPS (diluted)
−$0.61
Free cash flow
−$18.1M
−1279.2% margin
Valuation
Market cap
$8.4M
19.7M shares
P/E
–
No P/E while losing money
Price to sales
6.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.5M
At Sep 30
Shareholder equity
$2.3M
Shares outstanding
19.7M
At Nov 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $10.0M$10.0MFY2022FY2023: $2.8M$2.8MFY2023FY2024: $10K$10KFY2024FY2025: $1.0M$1.0MFY2025

From DARE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated DARE in the past 90 days, not enough for a consensus
Average 12-month target
$2.00
▲ 366.2% upside

Based on 1 analyst who set a price target on DARE in the past 90 days. The average target is $2.00, with a high of $2.00 and a low of $2.00, compared with the last close of $0.43.

Low $2.00Avg $2.00High $2.00
Blue marker: last close $0.43
Highest target$2.00
Average target$2.00
Lowest target$2.00
Latest rating changes
Ladenburg ThalmannAssumed coverage
Oct 26Buy$2
DateFirmActionRatingPrice target
Oct 26Ladenburg ThalmannAssumed coverageBuy$2
Loading…

Technical Analysis

DARE · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 51% below its 20 day and 68% below its 50 day average. It is 251% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $0.41, and the nearest resistance the Pivot at $0.48.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 13.7%/day
Key levels
$3.7852 week high+779.1%
$1.50200 day average+248.8%
$1.03100 day average+139.5%
$0.7250 day average+67.4%
$0.71Swing high (Nov 11)+65.1%
$0.6520 day average+51.2%
$0.54Pivot R1+25.6%
$0.48Pivot+11.6%
$0.43Last close
$0.4152 week low−4.7%
$0.37Pivot S1−14.0%
Indicators
RSI (14)21.57Oversold below 30Oversold
MACD-0.05Below its signal lineBearish
Stochastic11.9Near the bottom of its rangeOversold
ADX (14)24.4Weak trend
Williams %R-95.7Oversold below −80, overbought above −20Oversold
CCI (20)-439.9Oversold below −100, overbought above 100Oversold
Rate of change−32.1%Change over 10 sessionsBearish
ATR (14)$0.06Typical daily range, 13.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for DARE

What happened before

See how DARE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow DARE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How DARE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in DARE in the last 90 days.

Loading…

See today’s whale options flow across the market →

DARE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲20 buying vs 9 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +10
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3727+37.0%
In funds' top 1000–
Held by funds8.9%6.6%+2.2 pts
New / increased14 / 67 / 11+11.1%
Reduced / sold out5 / 44 / 50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See DARE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether DARE is in one of them and how their past DARE trades turned out.

DARE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered DARE in an article yet. Here's the latest on the wider market.

About Dare Bioscience

Dare Bioscience is a biotech company based in San Diego, California, that develops products for women's health. Its portfolio covers areas such as contraception, menopause, sexual health, pelvic pain, fertility, and vaginal health. The company plans to offer prescription products, compounded drugs, and consumer health products that do not need a prescription, mainly for women and the healthcare providers who treat them. Its first FDA-approved product, a treatment for bacterial vaginosis, is licensed to another drugmaker for sale.

Headquarters
San Diego, CA